SURPRISING ACTIVITY OF FLUTAMIDE WITHDRAWAL, WHEN COMBINED WITH AMINOGLUTETHIMIDE, IN TREATMENT OF HORMONE-REFRACTORY PROSTATE-CANCER

被引:110
作者
SARTOR, O
COOPER, M
WEINBERGER, M
HEADLEE, D
THIBAULT, A
TOMPKINS, A
STEINBERG, S
FIGG, WD
LINEHAN, WM
MYERS, CE
机构
[1] NCI, CLIN PHARMACOL BRANCH, BETHESDA, MD 20892 USA
[2] NCI, BIOSTAT & DATA MANAGEMENT SECT, BETHESDA, MD 20892 USA
[3] NCI, SURG BRANCH, DIV CANC TREATMENT, BETHESDA, MD 20892 USA
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 1994年 / 86卷 / 03期
关键词
D O I
10.1093/jnci/86.3.222
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The best treatment for patients with ''hormone-refractory'' metastatic prostate cancer is unclear, particularly in patients for whom suramin and hydrocortisone have failed. Purpose: We investigated a combination of flutamide withdrawal and aminoglutethimide in suramin- and hydrocortisone-pretreated patients with ''hormone-refractory'' prostate cancer. Methods: Twenty-nine patients with metastatic prostate cancer were treated with simultaneous flutamide withdrawal and aminoglutethimide (250 mg given orally four times daily). All patients were taking flutamide at the time of entry, and previous treatments with medical or surgical castration, flutamide, suramin, and hydrocortisone had failed in all of these patients. Because of suramin-induced adrenal insufficiency, all patients had previously received, and continued to receive, physiological doses of hydrocortisone. Treatment of all nonsurgically castrated patients had previously failed; however, these patients continued to receive depot leuprolide. Results: In 14 (48%) of 29 patients, the prostate-specific antigen (PSA) decreased by more than 80% for 4 or more weeks. Improvements in anemia, thrombocytopenia, soft-tissue masses, bone scans, and symptoms were also noted. Factors associated with response included prolonged flutamide pretreatment, a markedly elevated pretreatment PSA, and the absence of soft-tissue disease. Conclusions: Flutamide withdrawal, when combined with the simultaneous administration of aminoglutethimide, is a therapeutically active approach in patients with ''hormone-refractory'' prostate cancer. Implications: On the basis of these and additional data, we hypothesize that prolonged exposure to flutamide results in the selective proliferation of cancer cells containing a mutant androgen receptor that aberrantly recognizes flutamide metabolites and nonandrogenic steroids as androgenic stimuli.
引用
收藏
页码:222 / 227
页数:6
相关论文
共 42 条
[1]   UPDATE OF HORMONAL TREATMENT IN CANCER OF THE PROSTATE [J].
ALIVIZATOS, G ;
OOSTERHOF, GON .
ANTI-CANCER DRUGS, 1993, 4 (03) :301-309
[2]   TREATMENT OF STAGE D2 PROSTATIC-CANCER REFRACTORY TO OR RELAPSED FOLLOWING CASTRATION PLUS ESTROGENS - COMPARISON OF AMINOGLUTETHIMIDE PLUS HYDROCORTISONE WITH MEXDROXYPROGESTERONE ACETATE PLUS HYDROCORTISONE [J].
BEZWODA, WR .
BRITISH JOURNAL OF UROLOGY, 1990, 66 (02) :196-201
[3]   A STUDY OF AMINOGLUTETHEMIDE AND HYDROCORTISONE IN PATIENTS WITH ADVANCED AND REFRACTORY PROSTATE CARCINOMA [J].
CHANG, AYC ;
BENNETT, JM ;
PANDYA, KJ ;
ASBURY, R ;
MCCUNE, C .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1989, 12 (04) :358-360
[4]   A CONTROLLED TRIAL OF LEUPROLIDE WITH AND WITHOUT FLUTAMIDE IN PROSTATIC-CARCINOMA [J].
CRAWFORD, ED ;
EISENBERGER, MA ;
MCLEOD, DG ;
SPAULDING, JT ;
BENSON, R ;
DORR, FA ;
BLUMENSTEIN, BA ;
DAVIS, MA ;
GOODMAN, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (07) :419-424
[5]   GOSERELIN ACETATE AND FLUTAMIDE VERSUS BILATERAL ORCHIECTOMY - A PHASE-III EORTC TRIAL (30853) [J].
DENIS, LJ ;
DEMOURA, JLC ;
BONO, A ;
SYLVESTER, R ;
WHELAN, P ;
NEWLING, D ;
DEPAUW, M ;
FLANIGAN, RC .
UROLOGY, 1993, 42 (02) :119-130
[6]   LOW-DOSE AMINOGLUTETHIMIDE IN POSTMENOPAUSAL BREAST-CANCER - EFFECTS ON ADRENAL AND THYROID-HORMONE SECRETION [J].
DOWSETT, M ;
MEHTA, A ;
CANTWELL, BMJ ;
HARRIS, AL .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (07) :846-849
[7]   RESPONSE TO FLUTAMIDE WITHDRAWAL IN ADVANCED PROSTATE-CANCER IN PROGRESSION UNDER COMBINATION THERAPY [J].
DUPONT, A ;
GOMEZ, JL ;
CUSAN, L ;
KOUTSILIERIS, M ;
LABRIE, F .
JOURNAL OF UROLOGY, 1993, 150 (03) :908-913
[8]   A REEVALUATION OF NONHORMONAL CYTO-TOXIC CHEMOTHERAPY IN THE TREATMENT OF PROSTATIC-CARCINOMA [J].
EISENBERGER, MA ;
SIMON, R ;
ODWYER, PJ ;
WITTES, RE ;
FRIEDMAN, MA .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (06) :827-841
[9]   SURAMIN, AN ACTIVE-DRUG FOR PROSTATE-CANCER - INTERIM OBSERVATIONS IN A PHASE-I TRIAL [J].
EISENBERGER, MA ;
REYNO, LM ;
JODRELL, DI ;
SINIBALDI, VJ ;
TKACZUK, KH ;
SRIDHARA, R ;
ZUHOWSKI, EG ;
LOWITT, MH ;
JACOBS, SC ;
EGORIN, MJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (08) :611-621
[10]   HIGH-DOSE INTRAVENOUS ESTROGEN THERAPY IN ADVANCED PROSTATIC-CARCINOMA - USE OF SERUM PROSTATE-SPECIFIC ANTIGEN TO MONITOR RESPONSE [J].
FERRO, MA ;
GILLATT, D ;
SYMES, MO ;
SMITH, PJB .
UROLOGY, 1989, 34 (03) :134-138